The Trump administration’s new drug pricing initiative, TrumpRx, is creating meaningful conversation across the benefits industry. By pushing direct-to-consumer drug pricing and aggressive cost-reduction measures, the program has the potential to shift how prescription benefits are structured within employer-sponsored health plans nationwide.
For brokers and consultants, the takeaway is simple: change is coming, and preparing your clients now will put them in a stronger position later. Here’s what to watch.
TrumpRx is designed to lower pharmacy costs by:
While these goals may lower out-of-pocket costs for some consumers, they also challenge the traditional PBM structure employers rely on today. As the landscape evolves, employers may experience:
This is where brokers play an increasingly important role, helping clients navigate uncertainty and maintain plan stability without sacrificing quality or cost efficiency.
A proactive approach will set your clients up for success. Consider:
At 90 Degree Benefits, we help brokers turn uncertainty into opportunity. Our pharmacy cost-containment expertise, including RightTurnRx™, gives you the tools to:
We’re here to help you evaluate evolving policy changes, protect your clients’ bottom lines, and deliver a smarter pharmacy benefit strategy no matter how the market shifts.
TrumpRx may lower certain drug prices by introducing government-negotiated, direct-to-consumer pricing. However, it could also create new variability in employer pharmacy
costs. Because TrumpRx operates outside traditional PBM contracts, employers may see changes in formulary alignment, pricing guarantees, and rebate structures. In many cases, costs won’t disappear—they’ll shift. The real impact will depend on how individual plans are structured and how PBMs respond to federal pricing benchmarks.
Brokers should begin by reviewing each client’s current pharmacy benefit strategy to identify where pricing shifts could create risk or opportunity. Staying updated on TrumpRx guidance is essential, as the program is still evolving. Most importantly, brokers should proactively educate employers about potential changes and partner with pharmacy benefit experts who can help model scenarios, compare PBM options, and maintain cost stability during the transition.
No. TrumpRx does not replace PBMs. Instead, it introduces an alternative pathway for certain medications using government-negotiated prices. Employers will still rely on PBMs for formulary management, claims processing, specialty drug oversight, clinical programs, and network administration. TrumpRx may influence how PBMs structure contracts or pricing strategies, but it does not eliminate the need for PBM services in employer-sponsored health plans.
Ready to speak with an expert about your benefits strategy?
REFERENCES
“TrumpRx: How the Drug Pricing Program Works.” https://govfacts.org/explainer/trumprx-how-the-drug-pricing-program-works/ “Inside TrumpRx and its unusual launch.” https://cthosp.org/daily-news-clip/inside-trumprx-and-its-unusual-launch/ “Trump Announces ‘TrumpRx,’ a Government-Run Direct-To-Consumer Drug Website.” https://www.notus.org/healthcare/drug-prices-trumprx-pfizer “Creating unique health plan solutions – 90 Degree Benefits.” https://90degreebenefits.com/solutions/